Jerry Miller PhD is co-founder and a co-principal investigator on a multisite research team that has developed a new molecule that looks for receptor sites on the cells of patients and can be used to diagnose diabetes prevent diabetic ketoacidosis or get a good sense of glucose control.

The other co-principal investigator on the team Aaron Sinclair PhD is the Frederick A. and Susan G. Gorcher Professor at Harvard Medical School.

Millers lab has recently reported results in a paper in Nature.

The Miller Lab is a three-year 2. 5 million NIH research and development project with the aim of finding a way to improve glucose control in people with diabetes the second largest chronic disease after cancer according to the U. S. Centers for Disease Control and Prevention. Now they have developed a new molecule that could help to prickly control blood glucose levels faster. The molecule is based on glucose sensor proteins found in possibly the most elusive places on the human body: the circulatory system.

Miller Gorcher and their lab team considered the circulatory system a great model to study drug resistance and develop a new protein. They looked forward to meeting with several metabolic health experts in a special field conference that was set up to discuss glucose tolerance and safety. When you restrict glucose then you lose the activation the signaling ability and the ability to control blood glucose. You lose the ability to move the blood glucose without moving the own glucose. Blood glucose mitigation would reduce that. So we thought lets make a molecule that can do both Miller says. That we can use in a laboratory to make a long-distance short-distance test.

In the lab they used a screening procedure called HDFIX-A which involved filtering sugar (glucose) from the blood which enabled them to detect individual receptor sites on the cells. They found many receptor sites and could distinguish the sites with high glucose sensitivity. Also they found that those individual receptors were much more strongly oxidized than the resting glycemic index of the subjects.

Building on these findings they sought to find the simplest way to cure the nutrient-concentration protein CRISPR. It is a gene-editing tool used in many cancerous and HIV-infected cells. We went off the rails when we tried to use CRISPR in arthritis and found that CRISPR couldnt be turned back to its normal function Miller says. So we figured this would probably work in obesity.

Building a computational tool is a relatively simple task. Millers lab has been using GLIME an open source open-source computational tool and library to analyze the glucose level readings from cancer therapies and IRBGALC a protein indicator developed by Sinclair. We put GLIME to the ridiculous task of crunching GLIM levels in either type 1 or type 2 diabetic patients and then identified glucose levels in question Miller says.

They then set out to develop IRBGALC that can also be used to condition the urine and heart to validate glucose levels.

Miller says that IRBGALC has both practical and computational use enabling scientists to test therapeutics before they have them in human clinical at a very low dose.

The Miller Lab currently expects IRB-GRADE clinical trials to begin this fall testing the new glucose-sensing molecule to determine in patients whether it can detect diabetic ketoacidosis or improve blood glucose control. It certainly looks like the drug has potential in terms of potential to treat diabetic ketoacidosis.